SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-expressing Advanced Solid Tumors

Conditions

HER2-expressing Advanced Solid Tumors

Trial Timeline

Aug 11, 2023 → Dec 29, 2026

NCT ID

NCT06015048

About SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies

SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for HER2-expressing Advanced Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06015048. Target conditions include HER2-expressing Advanced Solid Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06015048	Phase 1/2	Recruiting	Aug 11, 2023	Dec 29, 2026	HER2-expressing Advanced Solid Tumors

Competing Products

6 competing products in HER2-expressing Advanced Solid Tumors

See all competitors

Product	Company	Stage	Hype Score
SHR-4602	Jiangsu Hengrui Medicine	Phase 2	42
VIR-5818 + pembrolizumab	Merck	Phase 1/2	39
ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine	Jazz Pharmaceuticals	Phase 2	32
Zanidatamab + Evorpacept	Jazz Pharmaceuticals	Phase 1/2	29
ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib	Jazz Pharmaceuticals	Phase 1	26
ZW49	Zymeworks	Phase 1	23